Loading…
Pasithea Therapeutics Corp. is projected to rise to $0.5355 by 2027, a +9% move from its current price of $0.4924. KTTA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.4761 | $0.4925 | $0.5095 | +0.03% |
| Jul 15 | $0.4696 | $0.4926 | $0.5169 | +0.05% |
| Jul 16 | $0.4647 | $0.4928 | $0.5226 | +0.08% |
| Jul 17 | $0.4606 | $0.4929 | $0.5275 | +0.10% |
| Jul 18 | $0.457 | $0.493 | $0.5319 | +0.13% |
| Jul 19 | $0.4538 | $0.4931 | $0.5359 | +0.15% |
| Jul 20 | $0.4509 | $0.4933 | $0.5396 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4509 | $0.4933 | $0.5396 | +0.18% |
| Week 2 | $0.4353 | $0.4941 | $0.561 | +0.36% |
| Week 3 | $0.4238 | $0.495 | $0.5783 | +0.53% |
| Week 4 | $0.4144 | $0.4959 | $0.5934 | +0.71% |
| Week 5 | $0.4065 | $0.4968 | $0.6072 | +0.89% |
| Week 6 | $0.3995 | $0.4977 | $0.62 | +1.07% |
| Week 7 | $0.3932 | $0.4986 | $0.6321 | +1.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate PAS-004 is a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
The company\'s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp.
was incorporated in 2020 and is headquartered in Miami Beach, Florida.
KTTA is Pasithea Therapeutics Corp., a healthcare company whose stock trades with a current price of $0.5261 and a market capitalization of $17.58M. It is ranked 4690 by market position.
A major floor 30.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.1% away) — a key level to hold.
The nearest ceiling, 45.2% above — a clean break opens room to run.
A major ceiling 73.6% above — clearing it would confirm fresh momentum.
Key KTTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KTTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5088 | Sell | $0.5084 | Sell |
| MA 10 | $0.5245 | Sell | $0.5209 | Sell |
| MA 20 | $0.536 | Sell | $0.5456 | Sell |
| MA 50 | $0.6479 | Sell | $0.6162 | Sell |
| MA 100 | $0.7108 | Sell | $0.6898 | Sell |
| MA 200 | $0.7896 | Sell | $0.8599 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.04 | Neutral |
| Stoch RSI (14) | 8.40 | Buy |
| CCI (20) | -111.45 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -13.38 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.94 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 41.36 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.49 | Sell |
| ADX (14) | 28.02 | Sell |
| ATR (14) | 0.02 | Info |
Sentiment in the near term is NEUTRAL. The RSI14 reads 30, and the 50-day simple moving average (SMA50) is $0.6764 while the 200-day simple moving average (SMA200) is $0.7986, providing a framework of resistance near $0.78 and support near $0.50.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.492 | $0.4924 | $0.6999 | 0% | Neutral | |
| $0.4167 | $0.5355 | $0.7334 | +9% | Neutral | |
| $0.403 | $0.5365 | $0.7682 | +9% | Neutral | |
| $0.3753 | $0.5147 | $0.7628 | +5% | Neutral | |
| $0.3329 | $0.4688 | $0.7152 | -5% | Neutral | |
| $0.3663 | $0.5284 | $0.8266 | +7% | Neutral | |
| $0.3768 | $0.5561 | $0.8896 | +13% | Neutral | |
| $0.4058 | $0.6118 | $0.9987 | +24% | Bullish | |
| $0.4689 | $0.7216 | $1.20 | +47% | Bullish | |
| $0.4318 | $0.6776 | $1.15 | +38% | Bullish | |
| $0.5316 | $0.9129 | $1.66 | +85% | Bullish | |
| $0.6909 | $1.39 | $2.81 | +183% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.492 | $0.4924 | $0.609 | +0.00% |
| August 2026 | $0.433 | $0.5144 | $0.6298 | +4.47% |
| September 2026 | $0.4205 | $0.5039 | $0.6255 | -2.04% |
| October 2026 | $0.4294 | $0.5184 | $0.6509 | +2.88% |
| November 2026 | $0.4494 | $0.5461 | $0.6922 | +5.33% |
| December 2026 | $0.4477 | $0.5473 | $0.6999 | +0.21% |
Click any year to see its month-by-month KTTA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KTTA to range from $0.492 to $0.6999 through 2026. The $0.4924 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The KTTA price prediction for 2027 points to an average of $0.5355 (low $0.4167, high $0.7334) — a potential gain of +9% on today's $0.4924. Price action looks broadly range-bound.
In 2028, KTTA is projected to trade between $0.403 and $0.7682, averaging $0.5365 — a potential gain of +9% from today's $0.4924. That is up 0% on the projected 2027 average. A consolidation phase looks the most probable path here.
Pasithea Therapeutics Corp.'s 2029 outlook centres on $0.5147, within a $0.3753 to $0.7628 range. That is -4% versus the projected 2028 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2030, KTTA could reach as high as $0.7152, with a base case around $0.4688 and support toward $0.3329 — roughly -5% from $0.4924. A consolidation phase looks the most probable path here.
Expect KTTA to range from $0.3663 to $0.8266 through 2031. The $0.5284 average target implies a +7% move from current prices. That is up +13% on the projected 2030 average. Price action looks broadly range-bound.
The KTTA price prediction for 2032 points to an average of $0.5561 (low $0.3768, high $0.8896) — a potential gain of +13% on today's $0.4924. A consolidation phase looks the most probable path here.
In 2033, KTTA is projected to trade between $0.4058 and $0.9987, averaging $0.6118 — a potential gain of +24% from today's $0.4924. That is up +10% on the projected 2032 average. Momentum favours further upside here.
Pasithea Therapeutics Corp.'s 2034 outlook centres on $0.7216, within a $0.4689 to $1.20 range. That is up +18% on the projected 2033 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, KTTA could reach as high as $1.15, with a base case around $0.6776 and support toward $0.4318 — roughly +38% from $0.4924. Momentum favours further upside here.
Expect KTTA to range from $0.5316 to $1.66 through 2040. The $0.9129 average target implies a +85% move from current prices. That is up +35% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The KTTA price prediction for 2050 points to an average of $1.39 (low $0.6909, high $2.81) — a potential gain of +183% on today's $0.4924. Momentum favours further upside here.
Investing $1,000 in KTTA today (≈ 2,030.869212 KTTA) could be worth
$2,829.05
+$1,829.05 (+183%) by 2050 · US Dollar
Based on the average projected KTTA price of $1.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KTTAwould be worth at today's price.
$1,000 invested in KTTA on Jul 10, 2025 (≈ 1,447.178035 KTTA) would be worth
$712.59
-$287.41 (-28.7%) today · 0.71× · US Dollar
Based on a KTTA entry price of $0.691 vs. today's $0.4924.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.55 | $895.27 | -10.5% |
| 1 month ago | $0.58 | $848.97 | -15.1% |
| 3 months ago | $0.7 | $703.43 | -29.7% |
| 6 months ago | $0.905 | $544.09 | -45.6% |
| 1 year ago | $0.691 | $712.59 | -28.7% |
| All time (4.8y) ago | $71.2 | $6.92 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KTTA forecast.
Our base-case forecast reaches $0.98 around 2050.
Implied market cap at $0.98: $32.75M
The year-by-year forecast shows a neutral stance in 2026 with a min of $0.50, an avg of $0.5261, and a max of $0.7416, and a 0% ROI. By 2033 the outlook becomes bullish, with an avg of $0.6716 and a max of $1.10, yielding a 27.7% upside. The forecast Then strengthens further into 2034 ($0.7771 avg, $1.30 max, 47.7% ROI) and 2035 ($0.7121 avg, $1.21 max, 35.4% ROI).
Long-range optimism remains, with 2040 showing $0.997 avg and $1.82 max (89.5% ROI) and 2050 at $1.48 avg and $3.01 max (182.1% ROI). The sentiment shifts to BULLISH from 2033 onward, reflecting higher expected prices and substantial upside potential, though these are estimates and not guarantees. The forecast also notes volatility, with a 70% annualized volatility, and a path that includes meaningful upside over the coming decades.
Tap a question to reveal the answer.
In 2030 the forecast shows a min of $0.3561, an avg of $0.504, and a max of $0.7728, with an ROI of -4.2% and NEUTRAL sentiment.
The forecast suggests NEUTRAL sentiment through 2032, with price averages rising later to a 2050 avg of $1.48 and a max of $3.01, corresponding to a 182.1% ROI in 2050. This path includes higher potential upside but also uncertainty.
Yes. The 2033 max is $1.10, the 2034 max is $1.30, the 2035 max is $1.21, the 2040 max is $1.82, and the 2050 max is $3.01, indicating multiple years with potential above $1.
Current price is $0.5261 and market cap is $17.58M.
The 2033 forecast shows an avg of $0.6716, a min of $0.4427, a max of $1.10, with a 27.7% ROI and bullish sentiment.
Pasithea Therapeutics Corp. Community Discussion
0Share your Pasithea Therapeutics Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.